regulation of chronic myelogenous leukemia CD34 + cell proliferation: BCR/ABL upregulates the cyclin-dependent kinase inhibitor, p27 Kip1 , which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci USA 2000; 97: 10538-10543. 8 Acquired uniparental disomy following mitotic recombination results in homozygosity for the V617F JAK2 mutation in a proportion of patients with myeloproliferative disorders (MPD), particularly polycythemia vera (PV) and myelofibrosis (MF). 1 Recently, Hammond et al. 2 in a letter in Leukemia indicated that a proportion of MPDs harbor more than two copies of V617F JAK2 and suggested that disease evolution may involve further gene duplication associated with genetic instability. In a followup study, the same group found that this phenomenon was most prevalent in PV, with more than one-third of mutation-positive cases apparently having more than two V617F copies/cell. 3 Increased V617F copy number has been described in cell lines, 4 but has not thus far been verified in patients.
To determine if elevated JAK2 copy number could be detected with an alternative methodology, we developed a test based on multiplex ligation-dependent probe amplification (MLPA), an established technique for detecting DNA copy number changes. [5] [6] [7] Four MLPA probe pairs targeting JAK2 exons 3, 9, 16 and 20 were designed, so that they could be combined with the commercially available telomere MLPA probe mix (P036B MRC-Holland, Amsterdam). The JAK2 probes consisted of adjacent 5 0 and 3 0 oligonucleotides which, when amplified by universal primers following the hybridization and ligation steps, generated products in the size range 98-126 bp. The 3 0 oligonucleotides for each probe pair were modified with a phosphate group at their 5 0 end, and each oligonucleotide pair contained a tag sequence recognized by the MLPA Salsa primers, so that the JAK2 probes were amplified alongside the telomere probes in one reaction. MLPA was performed and results were analyzed as described. 7, 8 Ratios of test peaks to control peaks and control peaks to other control peaks in each patient sample were compared to the same ratios obtained for two normal individuals that were included in each run. The four JAK2 peak area ratios per sample were averaged to give a relative dosage quotient for JAK2 as a representation of copy number per cell. For normal sequences, a dosage quotient of 1.0 is expected; if a deletion or duplication is present, the dosage quotient should be 0.5 and 1.5, respectively.
To validate the assay, we initially analyzed a series of control samples. Twenty-one hematologically normal individuals gave a median JAK2 dosage quotient of 1.01 (range 0.71-1.28). The dosage quotient for a fibroblast cell line carrying a der(9)t(6;9) was 0.50, corresponding to deletion of one copy of JAK2, which was further supported by deletion of one copy of the 9p telomere probe. To control for increased copy number of the JAK2 locus, the V617F-positive cell lines SET-2 and HEL were analyzed. SET-2 has approximately 75% V617F, as determined by pyrosequencing, 8 while MLPA revealed approximately five copies of the 9p telomere (dosage quotient ¼ 2.47) and five copies of JAK2 per cell (dosage quotient ¼ 2.50). HEL has 100% mutant allele by pyrosequencing and MLPA indicated 9-10 copies of JAK2 (dosage quotient ¼ 4.72), plus total deletion of the 9p telomere and other abnormalities. These results are illustrated in Figure 1 , and accord well with previous estimates of JAK2 copy number in these cell lines determined by fluorescence in situ hybridization. 4 Next, we investigated peripheral blood leukocyte DNA from 63 MPDs (PV, n ¼ 45; MF, n ¼ 5; other MPD, n ¼ 13) that were homozygous for V617F as determined by pyrosequencing (median %V617F ¼ 87%; range 63-99%). The JAK2 dosage quotients (median 0.99; range 0.67-1.25) ascertained by MLPA were no different from the normal control group and no case was above the previously defined cut-off required to define a duplication. 6, 7 Analysis of a further 16 heterozygous V617F cases (median %V617F ¼ 31%) yielded similar results with again no evidence for increased JAK2 copy number. Although Hammond et al. suggested that their results could be caused by an internal tandem duplication of the V617F region rather than a complete duplication of JAK2, such abnormalities have never been reported on amplification of JAK2 exon 14 from genomic DNA and, in addition, we have not detected any aberrant size bands using cDNA-specific primers to exons 13 and 15 in 15 homozygous V617F-positive cases analyzed by RT-PCR. We conclude therefore that amplification of the mutant JAK2 allele is not a common factor in the evolution of JAK2 V617F-positive disease. 
Figure 1
Representative MLPA genotyper traces for measuring JAK2 copy number per cell. The JAK2 probes for exons 9, 20, 16 and 3 result in smaller bands than those from MRC-Holland telomere probe mix, of which 1p-12p are shown here. The JAK2 dosage quotient and estimated copy numbers are shown. The der(9)t(6;9) cell line, which harbors only one copy of JAK2, shows reduced JAK2 and 9p subtelomere peaks relative to the other peaks. HEL and SET-2 show an increase in the relative size of these peaks, while no JAK2 copy number alterations were detected in four illustrative patient samples with a high %V617F.
Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disorder that can be subdivided into several subtypes based on DNA microarray-based gene expression profiling: germinal center B-cell-like (GC) DLBCL and activated B-cell-like (ABC) DLBCL. Patients with GC DLBCL have been shown to exhibit a more favorable clinical outcome than patients with non-GC DLBCL. 1 As with cDNA microarray, immunohistochemistry can also be used to distinguish the GC/non-GC subtype of DLBCL and to predict survival, 2 but there have been few reports comparing clinical outcomes in cases of GC DLBCL and non-GC DLBCL treated with rituximab. 3, 4 We retrospectively analyzed the treatment effect of rituximab with conventional chemotherapy on these two DLBCL subtypes by means of immunohistochemistry.
We analyzed patients with untreated DLBCL who were diagnosed according to the WHO classification. 5 Patients who were diagnosed in our hospital between 2001 and 2005 were treated with rituximab plus TCOP (R-TCOP) (cyclophosphamide, therarubicin, vincristine and prednisolone), and those who were diagnosed in our hospital between 1997 and 2002 were treated with TCOP alone. R-TCOP consisted of a combination of rituximab (375 mg/m 2 administered on day 1 of each chemotherapy cycle) and TCOP (cyclophosphamide 750, therarubicin 50 and vincristine 1.4 mg/m 2 administered on day 2 and prednisolone 100 mg/m 2 administered on days 2-6). TCOP consisted of TCOP alone. We reduced the chemotherapeutic dosage to two out of three patients who were more than 65 years of age. Tumor response was assessed at the end of treatment according to the International Workshop criteria. 6 Immunohistochemical staining was performed using heatinduced antigen retrieval, as described previously. 7, 8 Details of the immunohistochemical staining are provided in Table 1 . The scoring was based on the algorithm described by Hans et al. Bcl-6, CD10 and melanoma associated antigen (mutated) 1 (MUM1) were considered positive if 30% or more of tumor cells were stained with the respective antibody, and bcl-2 was considered positive if 30% or more tumor cells were stained.
Given that bcl-6 and CD10 are markers of GC B cells, a case was considered to be a case of GC DLBCL if CD10 alone was positive or if both bcl-6 and CD10 were positive. If both bcl-6 and CD10 were negative, the case was considered to be a case of non-GC DLBCL. If bcl-6 was positive and CD10 was negative, the expression of MUM1 was used to determine the group, that is if MUM1 was negative, the case was considered to be a case of GC DLBCL, and if MUM1 was positive, the case was considered to be a case of non-GC DLBCL.
The results of immunohistochemical staining and response rates were compared between groups using w 2 test and Fisher's exact test. Event-free survival (EFS) was calculated from the time of diagnosis to the date of disease progression, death or last contact. Overall survival (OS) was calculated as the time from diagnosis to the date of death or last contact. Survival curves were constructed using the Kaplan-Meier method and compared by log-rank test. Differences were considered significant at Po0.05. A general-purpose statistical software package, StatFlex Version 5.0 (Artech Co., Osaka, Japan), which provides results compatible with SPSS, was used for the data analyses.
The R-TCOP group comprises 38 patients. The median follow-up time for surviving patients in this group was 13 months. The TCOP group comprises 31 patients. The median follow-up time for surviving patients in this group was 25 months. Of the 69 cases in total, 26 (38%) and 43 (62%) were considered cases of GC DLBCL and non-GC DLBCL, respectively, on the basis of immunohistochemical analysis. In the R-TCOP group, 18 (48%) and 20 (52%) cases were classified as cases of GC DLBCL and non-GC DLBCL, respectively. In the TCOP group, eight (26%) and 23 (74%) cases were classified as cases of GC DLBCL and non-GC DLBCL, respectively. Bcl-2 was expressed in 63% of cases in the R-TCOP group, that is in 61% of GC DLBCL and 65% of non-GC DLBCL. Bcl-2 was expressed in 53% of cases treated with TCOP alone, that is in 50% of GC DLBCLs and in 70% of non-GC-DLBCLs. The patient characteristics (age, sex, performance status, Ann Arbor clinical stage, B symptoms, bone marrow involvement, extranodal disease, International Prognostic Index (IPI) and lactate dehydrogenase (LDH)) did not differ significantly between groups (that is, between patients grouped by treatment or by DLBCL subtype) ( Table 2) .
